Abcam’s aim is to serve life science researchers to achieve their mission, faster. We continuously listen, collaborate and support the scientific community in order to improve and offer new affinity binders, reagents, biomarkers and assays that will drive greater scientific progress. Our culture is a key differentiator. We believe in empowering individuals, with responsibility given at an early stage. The working environment is fun and fast-paced, collaborative and outcome focused, with a strong customer focus. In addition to competitive salaries we offer an attractive flexible benefits package with plenty of opportunities to learn and grow. Our head office is in Cambridge (UK), we also have offices in Bristol (UK), Cambridge, Eugene and San Francisco (USA), Tokyo (Japan), Hong Kong, Hangzhou and Shanghai (China). We have a range of roles in IT background and would normally look for candidates with a degree in computer science or other numerate disciplines. We also recruit positions for candidates with a scientific background and we would normally look for candidates with biological science qualifications.
Show more
Type
Public
HQ
Milton, GB
Founded
1998
Size (employees)
948 (est)+8%
Website
abcam.com
Abcam was founded in 1998 and is headquartered in Milton, GB
Report incorrect company information

Key People/Management at Abcam

Jonathan Milner

Jonathan Milner

CEO

Abcam Office Locations

Abcam has offices in San Francisco, Eugene, Tokyo, Milton and in 8 other locations
Milton, GB (HQ)
330 Cambridge Science Park Milton Rd
Cambridge, US (HQ)
b2304 One Kendall Square Binney St
Shanghai, CN
Galileo Rd. Pudong
Tokyo, JP
2-2-1 Nihonbashi Horidome-cho
Cambridge, US
b2304 1 Kendall Square
Show all (13)
Report incorrect company information

Abcam Financials and Metrics

Abcam Financials

Abcam's revenue was reported to be £217.10 m in FY, 2017
GBP

Revenue (FY, 2017)

217.1 m

Gross profit (FY, 2017)

152.1 m

Gross profit margin (FY, 2017), %

70.1%

Net income (FY, 2017)

42.4 m

EBITDA (FY, 2017)

70.5 m

EBIT (FY, 2017)

55.1 m

Market capitalization (31-Oct-2017)

2 b

Closing share price (31-Oct-2017)

9.8

Cash (30-Jun-2017)

84.8 m
Abcam's current market capitalization is £2 b.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

36.7 m56.8 m71.1 m83.3 m97.8 m122.2 m128 m144 m171.7 m217.1 m

Revenue growth, %

13%19%

Cost of goods sold

14.4 m19.4 m23.7 m27.2 m30.3 m35.5 m37.6 m42.5 m51.1 m65 m

Gross profit

22.3 m37.4 m47.4 m56 m67.6 m86.7 m90.4 m101.5 m120.5 m152.1 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.5 m25.5 m40.2 m55.6 m14 m37.3 m55.3 m57.1 m68.9 m84.8 m

Accounts Receivable

3.7 m5.4 m6.8 m7.9 m11.5 m12.1 m13.2 m19.6 m

Inventories

4.5 m6.8 m9.1 m10.7 m15.4 m15.3 m14.8 m19.8 m19.7 m21.8 m

Current Assets

23.9 m40.1 m58.5 m76.4 m48.7 m71.3 m90.9 m100.5 m119.7 m143.5 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

5.9 m12.3 m19.2 m23.8 m25.4 m32.7 m34 m37.4 m37.4 m42.4 m

Cash From Operating Activities

7.1 m14.8 m19.7 m25.5 m24.5 m39.4 m41.3 m40.2 m47.3 m66.4 m

Dividends Paid

2.6 m5.3 m7.9 m10.1 m12.5 m11.3 m15.9 m16.7 m19.1 m

Cash From Financing Activities

(2.2 m)(1.2 m)(27.4 m)(7.6 m)10.7 m(11.8 m)(13.8 m)(14.1 m)(15.4 m)(17.7 m)
GBPY, 2017

Revenue/Employee

237.3 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Abcam News and Updates

Protein Assays Market 10.8% of CAGR Expected by 2023 with Abcam plc, Lucigen Co, QIAGEN, Illumina Inc, Takara Bio Inc

Protein Assays Market Research Report– by Type (Copper-Ion-Based Assays, Test Strip-Based Assays, and Dye-Binding Assays), By Application (Diagnosis, Drug Discovery, and Protein Purification), By Product, By Technology, and By End User– Global forecast till 2023 Posted via Industry Today. Follow us …

Monoclonal Antibody Custom Service Market Accruals of Tremendous Growth by 2023 At 10.84% of CAGR

Monoclonal Antibody Custom Service Market provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market Posted via Industry Today. Follow us on Twitter @IndustryToday

Global Paper Diagnostics Market 2018 Share, Trend, Segmentation And Forecast To 2023

Paper Diagnostics -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Klebsiella Testing Market Augmented Expansion to be Registered by 2025

The global klebsiella testing market is expected to show a significant growth over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday

Future Scope of Monoclonal Antibody Custom Service Market | Top Players Analysis | Which is Estimated to grow at a CAGR of 10.84% | | Forecast to 2023

Market Research Future has a cooked research report on the monoclonal antibody custom service market. Monoclonal Antibody Custom Service Market is Projected to grow at a CAGR of 10.84% from 2017 to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information